| |
Total n = 78
|
TDF/ FTC n = 61
|
ABC/ 3TC n = 17
|
EFV n = 36
|
ATV/r n = 27
|
LPV/r n = 15
|
---|
IL-6
|
Baseline (pg/ml)
|
1.6 (1.1-2.5)
|
1.6 (1.1-2.6)
|
1.2 (0.99-1.7)
|
1.6 (1.1-2.5)
|
1.2 (0.88-2.4)
|
2.17 (1.1-7.4)
|
Mean fold change (95% CI)
|
0.60 (0.49, 0.74)
|
0.60 (0.48, 0.77)
|
0.60 (0.36, 0.99)
|
0.59 (0.42, 0.83)
|
0.82 (0.64, 1.05)
|
0.36 (0.20, 0.67)
|
P value*
|
<0.001
| | | | | |
hs-CRP
|
Baseline (mg/L)
|
4 (2.2-15)
|
4.2 (2.3-15)
|
2.7 (1.8-9.4)
|
3.9 (2.2-17.8)
|
3 (2-5.9)
|
7.5 (2.9-20)
|
Mean fold change (95% CI)
|
0.77 (0.57, 1.1)
|
0.81 (0.56, 1.20)
|
0.66 (0.33, 1.30)
|
0.76 (0.46, 1.26)
|
0.88 (0.54, 1.44)
|
0.63 (0.27, 1.47)
|
P value
|
0.11
| | | | | |
sCD14
|
Baseline (106 pg/ml)
|
2.6 (2.1-3.1)
|
2.6 (2.2-3.1)
|
2.5 (2-3.1)
|
2.5 (2.2-3)
|
2.6 (1.7-3.1)
|
3.1 (2-3.4)
|
Mean fold change (95% CI)
|
1.00 (0.93, 1.1)
|
1.00 (0.93, 1.10)
|
0.96 (0.79, 1.15)
|
0.95 (0.85, 1.06)
|
1.10 (0.93, 1.26)
|
1.00 (0.85, 1.20)
|
P value
|
0.82
| | | | | |
IP-10
|
Baseline (pg/ml)
|
664 (431-960)
|
630 (435-974)
|
721 (431-895)
|
692 (447-996)
|
549 (389-781)
|
798 (470-1326)
|
Mean fold change (95% CI)
|
0.41 (0.35, 0.49)
|
0.44 (0.36, 0.52)
|
0.37 (0.27, 0.49)
|
0.34 (0.28, 0.42)
|
0.53 (0.40, 0.71)
|
0.43 (0.27, 0.67)
|
P value
|
<0.001
| | | | | |
MIG
|
Baseline (pg/ml)
|
1532 (980-2804)
|
1534 (1004-2804)
|
1431 (938-2562)
|
1908 (1093-3799)
|
1182 (920-2201)
|
1611 (887-2444)
|
Mean fold change (95% CI)
|
0.26 (0.19, 0.33)
|
0.25 (0.18, 0.35)
|
0.27 (0.17, 0.42)
|
0.16 (0.10, 0.24)
|
0.39 (0.30, 0.51)
|
0.39 (0.22, 0.70)
|
|
P value
|
<0.001
| | | | | |
- TDF, Tenofovir; FTC, Emtricitabine; ABC, Abacavir; 3TC, Lamivudine; EFV, Efavirenz; ATV/r, Atazanavir/ritonavir; LPV/r, Lopinavir/ritonavir; IL-6, Interleukin-6; hs-CRP, Highly sensitive C-reactive protein; sCD14, soluble CD14; 1P10, Interferon-γ-Inducible Protein 10; MIG, Monokine induced by interferon-γ; CI, Confidence Interval.
- *One-sample Student’s t test of the change of each marker in the overall study sample.